Matthew Breeggemann

Matthew Breeggemann, MD, is an Assistant Professor in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine. He serves as the medical director of the nephrology-based Kidney Stone Prevention Center at UCSF and cares for patients with chronic kidney disease, electrolyte disorders, and acute kidney injury in both inpatient and outpatient settings.

Education and Training:

• BA in Biology, Carroll College (2012)
• MD, Creighton University School of Medicine (2016)
• Residency in Internal Medicine, Dartmouth-Hitchcock Medical Center (2019)
• Chief Residency in Internal Medicine, Dartmouth-Hitchcock Medical Center (2020)
• Fellowship in Nephrology, UCSF (2023)

Research Interests: Dr. Breeggemann’s work focuses on kidney stone prevention, genetic testing for monogenic kidney diseases (e.g., Primary Hyperoxaluria), and the pathophysiology of acute and chronic kidney injury. His research integrates clinical nephrology with translational studies on electrolyte disorders and the gut microbiome’s role in diabetic kidney disease.

Publications: His articles span genetic testing innovations, case reports on novel treatments for Primary Hyperoxaluria, and studies on electrolyte imbalances and microbiome contributions to kidney disease. Recent work emphasizes clinical applications of genetic insights and therapeutic advancements in nephrology.

Grants and Advising: While specific grants are not listed, his publications indicate active participation in collaborative research. He advises on clinical care protocols and contributes to nephrology education through residency and fellowship training.

Labs/Teams: As director of the Kidney Stone Prevention Center, he leads a team focused on translational research and patient care for nephrolithiasis. Collaborations include studies on Nedosiran therapy and microbiome-driven kidney disease mechanisms.